Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Andreas Gratz"'
Autor:
Alexander Schnitzler, Andreas Gratz, Andre Bollacke, Michael Weyrich, Uwe Kuckländer, Bernhard Wünsch, Claudia Götz, Karsten Niefind, Joachim Jose
Publikováno v:
Pharmaceuticals, Vol 11, Iss 1, p 23 (2018)
Human protein kinase CK2 is an emerging target for neoplastic diseases. Potent lead structures for human CK2 inhibitors are derived from dibenzofuranones. Two new derivatives, 7,9-dichloro-1,2-dihydro-8-hydroxy-4-[(4-methoxyphenylamino)-methylene]dib
Externí odkaz:
https://doaj.org/article/e600547616ff4022ba3097e5bc9ea5e6
Autor:
Christian Nienberg, Claudia Garmann, Andreas Gratz, Andre Bollacke, Claudia Götz, Joachim Jose
Publikováno v:
Pharmaceuticals, Vol 10, Iss 1, p 6 (2017)
Human protein kinase CK2 has emerged as promising target for the treatment of neoplastic diseases. The vast majority of kinase inhibitors known today target the ATP binding site, which is highly conserved among kinases and hence leads to limited sele
Externí odkaz:
https://doaj.org/article/b394dc6f196b47afa0d2e04c9dd1395a
Publikováno v:
Molecular and Cellular Biochemistry. 356:83-90
Protein kinase CK2 is emerging as a target in neoplastic diseases. Inhibition of CK2 by small compounds could lead to new therapies by counteracting the elevated CK2 activities found in a variety of tumors. Currently, CK2 inhibitors are primarily eva
Publikováno v:
Bioorganic & Medicinal Chemistry. 19:2666-2674
Reaction of 2,3-dichloro-5,6-dicyano-benzoquinone (DDQ) with secondary enaminones yields surprisingly 2-aza-spiro[4,5]decatrienes. The reaction occurs via cyclisation of the primary Michael-adduct with the nitrile group. Reaction of DDQ with tertiary
Autor:
Claudia Götz, Karsten Niefind, Joachim Jose, Michael Weyrich, Bernhard Wünsch, Uwe Kuckländer, Andreas Gratz, Andre Bollacke, Alexander Schnitzler
Publikováno v:
'Pharmaceuticals ', vol: 11, pages: 23-1-23-24 (2018)
Pharmaceuticals
Pharmaceuticals, Vol 11, Iss 1, p 23 (2018)
Pharmaceuticals; Volume 11; Issue 1; Pages: 23
Pharmaceuticals
Pharmaceuticals, Vol 11, Iss 1, p 23 (2018)
Pharmaceuticals; Volume 11; Issue 1; Pages: 23
Human protein kinase CK2 is an emerging target for neoplastic diseases. Potent lead structures for human CK2 inhibitors are derived from dibenzofuranones. Two new derivatives, 7,9-dichloro-1,2-dihydro-8-hydroxy-4-[(4-methoxyphenylamino)-methylene]dib
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry. 25:234-239
Besides cardiovascular diseases, cancer represents the major cause of death in developed countries. In many different human tumors, increased activity of serine/threonine protein kinase CK2 has been detected, and recent in vivo studies support a dire
Autor:
Zouhair Bouaziz, Gro Gausdal, Pascal Sonnet, Andre Bollacke, Joachim Jose, Attilio Di Pietro, Matthias U. Kassack, Catherine Mullié, Samar Issa, Andreas Gratz, Stein Ove Døskeland, Jacques Gentili, Camille Desgrouas, Lars Herfindal, Glaucio Valdameri, Marc Le Borgne, Milad Baitiche, Nicolas Taudon
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry
Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30 (2), pp.180-188. ⟨10.3109/14756366.2014.899594⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, Informa Healthcare, 2015, 30 (2), pp.180-188. ⟨10.3109/14756366.2014.899594⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30 (2), pp.180-188. ⟨10.3109/14756366.2014.899594⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, Informa Healthcare, 2015, 30 (2), pp.180-188. ⟨10.3109/14756366.2014.899594⟩
Four series of carbazole derivatives, including N-substituted-hydroxycarbazoles, oxazinocarbazoles, isoxazolocarbazolequinones, and pyridocarbazolequinones, were studied using diverse biological test methods such as a CE-based assay for CK2 activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53eb90ea3a51b4c1641c44d847ac0668
https://hal.science/hal-01683306
https://hal.science/hal-01683306
Autor:
Claudia Garmann, Claudia Götz, Andre Bollacke, Joachim Jose, Christian Nienberg, Andreas Gratz
Publikováno v:
Pharmaceuticals
Pharmaceuticals; Volume 10; Issue 1; Pages: 6
Pharmaceuticals, Vol 10, Iss 1, p 6 (2017)
Pharmaceuticals; Volume 10; Issue 1; Pages: 6
Pharmaceuticals, Vol 10, Iss 1, p 6 (2017)
Human protein kinase CK2 has emerged as promising target for the treatment of neoplastic diseases. The vast majority of kinase inhibitors known today target the ATP binding site, which is highly conserved among kinases and hence leads to limited sele
Publikováno v:
Acta chimica Slovenica. 60(3)
Protein kinase CK2 (Casein Kinase 2) is involved in cell growth; proliferation and suppression of apoptosis. Hence, it strongly promotes cell survival and can be considered an important target for human cancers. In the present study, a series of N-su
Publikováno v:
Biochimica et biophysica acta. 1820(7)
Background Abnormally high activity of protein kinase CK2 is linked to various diseases including cancer. Therefore, the inhibition of CK2 is a promising therapeutic strategy to fight this disease. Methods We screened a library of synthetic molecules